Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Atara Biotherapeutics (ATRA) EBIT Margin (2022 - 2025)

Atara Biotherapeutics (ATRA) has disclosed EBIT Margin for 4 consecutive years, with 103.5% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBIT Margin fell 4937.0% year-over-year to 103.5%, compared with a TTM value of 17.26% through Sep 2025, up 14708.0%, and an annual FY2024 reading of 64.71%, up 315477.0% over the prior year.
  • EBIT Margin was 103.5% for Q3 2025 at Atara Biotherapeutics, down from 18.19% in the prior quarter.
  • Across five years, EBIT Margin topped out at 39.53% in Q1 2025 and bottomed at 9005.55% in Q2 2023.
  • Average EBIT Margin over 4 years is 1686.18%, with a median of 108.86% recorded in 2024.
  • The sharpest move saw EBIT Margin plummeted -111092bps in 2023, then soared 894189bps in 2024.
  • Year by year, EBIT Margin stood at 118.82% in 2022, then plummeted by -935bps to 1229.74% in 2023, then skyrocketed by 97bps to 37.26% in 2024, then tumbled by -178bps to 103.5% in 2025.
  • Business Quant data shows EBIT Margin for ATRA at 103.5% in Q3 2025, 18.19% in Q2 2025, and 39.53% in Q1 2025.